TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be 50 years of age or older with NINCDS-ADRDA defined possible or probable AD~* Patient must have psychotic symptoms that developed after the diagnosis of AD was established. These symptoms must include visual and/or auditory hallucinations, and/or delusions~* Patient must have been a nursing home resident for ≥ 4 weeks prior to randomization, not bedridden and expected to remain in the facility throughout the study~* Patient must have actively experienced and verbally communicated psychotic symptoms during the month prior to the Screening visit and weekly during the previous 2 weeks prior to Baseline~* If patient is on acetylcholinesterase inhibitor (AChEI) therapy and/or memantine, must be on stable doses for 3 months prior to the Baseline visit and during the study~* Patient is willing and able to provide informed consent. If the subject is unable to provide written consent due to the severity of dementia, consent must be given by a legally authorized representative~Exclusion Criteria:~* Patient has a history of significant psychotic disorders prior to or concomitantly with the diagnosis of Alzheimer's disease including, but not limited to, schizophrenia or bipolar disorder~* Patient is unable to communicate verbally~* Patient has current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, renal, hematologic or other medical disorder, including cancer or malignancies, which would affect the patient's ability to participate in the study~* Patient has had a myocardial infarction in the last six months~* Patient has moderate to severe congestive heart failure~* Patient has any surgery planned during the screening, treatment, or follow-up periods that could interfere with participation in the study per the protocol assessments~Patients will be evaluated at screening to ensure that all criteria for study participation are met. These evaluations will include specific measures of psychosis severity, delirium, dementia, cardiovascular condition, and pregnancy status. Patients may be excluded from the study based on these assessments (and specifically if it is determined that their baseline health and psychiatric condition do not meet all protocol-specified entry criteria).

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, two tablets, once daily by mouth
- Pimavanserin 40 mg (Type: EXPERIMENTAL): Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females between 18 and 65 years, inclusive, at time of Screening~* Females must be post-menopausal for more than 2 years or surgically sterile or practicing abstinence/specific forms of birth control~* Subject has never received antiviral treatment for hepatitis C infection~* Chronic HCV Genotype-1 infection prior to study enrollment~Exclusion Criteria:~* Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human Immunodeficiency virus antibody (HIV Ab)~* Females who are pregnant or plan to become pregnant, or breastfeeding~* Any current or past clinical evidence of cirrhosis~* Screening laboratory analyses that showing abnormal laboratory results~* Use of contraindicated medications within 2 weeks of dosing and subject with contraindication for telaprevir, pegIFN and RBV~* Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol~* Positive screen for drugs or alcohol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm A: 3-DAA + RBV in GT1a (Type: EXPERIMENTAL): ABT-450/r/ABT-267 150 mg/100 mg/25 mg once daily (QD) and ABT-333 250 mg twice daily (BID) and weight-based RBV for 12 weeks (3 direct-acting antivirals \[DAAs\] with RBV in GT1a)
- Arm B: TPV/PR in GT1a (Type: ACTIVE_COMPARATOR): Telaprevir (TPV) 750 mg every 8 hours (q8h) and pegIFN 180 µg/week and weight-based RBV (PR) for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1a)
- Arm C: 3-DAA + RBV in GT1b (Type: EXPERIMENTAL): ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID and weight-based RBV for 12 weeks (3 DAAs with RBV in GT1b)
- Arm D: 3-DAA in GT1b (Type: EXPERIMENTAL): ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID for 12 weeks (3 DAAs without RBV in GT1b)
- Arm E: TPV/PR in GT1b (Type: ACTIVE_COMPARATOR): Telaprevir 750 mg q8h and pegIFN 180 µg/week and weight-based RBV for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1b)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Outcomes of Buffered vs. Non-Buffered Lidocaine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-30 years~* ASA I~* Willingness to complete QOL instrument~* Willingness to participate in two sessions~Exclusion Criteria:~* Allergy to lidocaine class of anesthetic drugs~* Local anesthetic drug use in past week~* Current symptoms teeth or oral mucosa

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Buffered Lidocaine (Type: ACTIVE_COMPARATOR): In week One each subject would receive anesthetic to block the inferior alveolar and lingual N; Halstead or Gow-Gates techniques. No Buccal N. block.~Venous blood samples would be drawn from the antecubital fossa 30min post oral injection and assayed for blood lidocaine levels
- Non-buffered Lidocaine (Type: ACTIVE_COMPARATOR): In week One each subject would receive anesthetic to block the inferior alveolar and lingual N; Halstead or Gow-Gates techniques. No Buccal N. block. At least a week later injections would involve the alternate local anesthetic combination.~Venous blood samples would be drawn from the antecubital fossa 30min post oral injection and assayed for blood lidocaine levels

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria for Mothers:~* HIV-infected~* At least at 26th week of pregnancy (treatment group) or 18th week of pregnancy (observational group) but not beyond the 34th week of pregnancy~* Able to complete study visits until at least 6 months postpartum~* Citizen of Botswana~Exclusion Criteria for Mothers:~* Taken ARVs for more than 1 week, other than ZDV, during current or prior pregnancy. Women who have received single-dose NVP in a prior pregnancy are not excluded.~* Certain abnormal laboratory values~* Plan to formula feed~* Known fetal abnormalities that suggest the fetus will not survive to 6 months of gestational age~* Known allergy or medical contraindication to any of the study drugs~* Require certain medications~* Previous participation in the Prevention of Milk-Borne Transmission of HIV-1C in Botswana (Mashi) study~* Currently incarcerated

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Trizivir (TZV) Arm (Type: EXPERIMENTAL): Participants in the TZV Arm (Arm 1A) will be pregnant women who have CD4 counts of 200 cells/mm3 or more. As the intervention, they will receive TZV twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
- Kaletra Arm (Type: EXPERIMENTAL): Participants in the Kaletra Arm (Arm 1B) will be pregnant women who have CD4 counts of 200 cells/mm3 or more. As the intervention, they will receive Lamivudine/Zidovudine (3TC/ZDV) and Lopinavir/Ritonavir (LPV/RTV) twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
- Nevirapine (NVP) Arm (Type: EXPERIMENTAL): Participants in the NVP Arm (Arm 2) will be pregnant women who have have CD4 counts less than 200 cells/mm3. These participants will receive NVP once daily for the first 14 days, then twice daily, and 3TC/ZDV twice daily; these women will be in the observational group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Use of Aerosolized Ribavirin for Treatment of RSV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with these underlying malignancies will be eligible for this study: Autologous BMT patients, Allogeneic BMT patients, and patients with hematological malignancy.~2. Patients must be at least 5 years of age.~3. Only patients with infection limited to the URT will be eligible for entry on study~4. Patients will be eligible for entry on study if a nasopharyngeal wash or throat swab specimen is positive by rapid RSV antigen testing or by a positive culture for RSV.~Exclusion Criteria:~1. Patients with evidence of RSV LRTI as documented by a positive rapid RSV antigen testing or by a positive culture for RSV from a nasopharyngeal wash or throat swab AND new infiltrates on chest radiograph and/or abnormal blood gas determination~2. Patients with hypersensitivity to ribavirin or its components~3. Pregnant women. Participants must practice birth control during the study if they are sexually active. If the participant is pregnant, she may not be enrolled on this study. Mothers should refrain from breast-feeding during the study to avoid injury to their children.~4. Patients with positive RSV by rapid testing or culture in bronchoalveolar lavage regardless of the chest radiographic results.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1: Standard Schedule - Ribavirin (Type: EXPERIMENTAL): Aerosolized Ribavirin 6 grams over 18 hours every 24 hours
- 2: Modified Schedule - Ribavirin (Type: EXPERIMENTAL): Aerosolized Ribavirin 2 grams over 3 hours every 8 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* the subject must have participated in previous Lamazym-trials: phase 2b: 2011-004355-40 or phase 3: 2012-000979-17~* Subject or subjects legally authorized guardian(s) must provide signed, informed consent prior to performing any trial-related activities~* The subject and his/her guardian(s) must have the ability to comply with the protocol~Exclusion Criteria:~* Presence of known clinically significant cardiovascular, hepatic, pulmonary, or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial~* Any other medical condition or serious intercurrent illness, or extenuating circumstances that, in the opinion of the Investigator, would preclude participation in the trial~* Pregnancy. Pregnant woman is excluded. Before start fot he treatment the investigators will for women of childbearing potential perform a pregnancy test and decide whether or not there is a need for contraception~* Psychosis; any psychotic disease, also in remission, is an exclusion criteria~* Planned major surgery that, in the opinion of the Investigator, would preclude participation in the trial~* Adult patients who, in the opinion of the Investigator, would be unable to give consent, and who does not have any legal protection or guardianship~* total IgE \> 800 IU/mL~* Known allergy to the IMP or any excipients (Sodium-Phosphate, Glycine, Mannitol)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lamazym (Type: EXPERIMENTAL): 1 mg Lamazym/kg body weight

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients - SANOB Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Signature of informed consent~* COPD patients with age raging from 50 to 85 years old~* Patients with at least a history of COPD of one year~* COPD patients clinically stable in the last three months~* COPD subjects with FEV1 (Forced Expiratory Volume in 1st second)\<70% of predicted value~* FEV1/FVC (Forced Expiratory Volume in 1st second/Forced Vital Capacity) \<88% (males) or \<89% (females) of LLN (Low Levels of Normality)~* COPD former or active smokers with at least a smoking history of 20 pack year~Exclusion Criteria:~* Acute Bronchial Exacerbation at recruitment~* Fertile women with age between 18 and 50 years old or with active period~* Pregnancy~* Subjects enrolled in other clinical trials or that have taken part in one of them in the month preceding the enrollment.~* FEV1/FVC more than 70% of predicted value in basal conditions~* FEV1 more than 70% of predicted value in basal conditions~* Known deficit of alpha 1 antitrypsin~* Subjects that underwent a Lung Volume Reduction Surgery (LVRS)~* Subjects with known positivity to Human Immunodeficiency Virus (HIV)~* Misuse of alcool or drugs~* Lack of compliance in performing respiratory tests~* Subjects not capable to follow the study prescriptions because of psychic disorders or language problems.~* Long Term Oxygen Therapy with flows \> 6 litres per minute (l/min) at rest

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Formoterol Fumarate (Type: EXPERIMENTAL): At study day n°1 the patients will be randomized to take either Salmeterol or Formoterol in a double blind way.
- Salmeterol (Type: ACTIVE_COMPARATOR): The second study arm represents the crossing over arm. Every patient, at study day number 2 will take a different medication (Salmeterol 50 mcg or Formoterol 12 mcg) from that taken at the study day n° 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Etanercept Treatment of Patients With Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Main inclusion criteria~* Diagnosis of AS (defined by Modified New York Criteria for Ankylosing Spondylitis).~* Active AS (defined by the average of scores on the visual analog scale \[VAS\] of ≥ 30 for duration and intensity of morning stiffness and by 2 of the following: VAS for patient global assessment ≥ 30; average of VAS for nocturnal and total pain ≥ 30; BASFI ≥ 30 (all scores on a scale of 0 to 100).~* 18 to 70 years of age.~Main exclusion criteria~* Complete ankylosis (fusion) of spine.~* Previous receipt of etanercept, antibody to tumour necrosis factor alpha (TNFα), or other TNFα inhibitors.~* Use of disease-modifying antirheumatic drugs (DMARDs) other than hydroxychloroquine, sulphasalazine, or methotrexate within 4 weeks of baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Sevelamer Carbonate on Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Evidence of CKD Stages II, III or IV~* Stage II CKD; eGFR 60-89 ml/min~* Stage III CKD: eGFR 30-59 ml/min~* Stage IV CKD: eGFR 15-29 ml/min~* Proteinuria (\>200 mg/day or 300 mg/gm creatinine on a spot urine) on urinalysis on two occasions within 18 months of recruitment~* Diagnosis of diabetes and receiving at least one medication for diabetes mellitus~* HbA1c\>6.5%~Exclusion criteria:~* Age \<18~* Patients receiving active treatment for hyperphosphatemia~* Biopsy proven renal disease other than diabetic nephropathy~* Hypophosphatemia~* Hypercalcemia~* Any history of significant gastrointestinal disorders~* Any history of significant gastrointestinal surgery such as ileostomy, colostomy and colectomy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sevelamer Carbonate (Type: EXPERIMENTAL): 1600 mg (two 800 mg in the form of tablets or powder to be diluted in water) TID with meals for 26 weeks
- calcium carbonate (Type: ACTIVE_COMPARATOR): 1200 mg of calcium carbonate TID with meals for 26 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* Diagnosis of low or intermediate-1 risk Myelodysplastic (MDS) with any chromosome karyotype except del 5q\[31\]~* Anemia that requires red blood cell transfusions~* Resistant to erythropoiesis stimulating agents (ESAs) or blood erythropoietin level \> 500 mU/mL~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2~* Must agree to follow pregnancy precautions as required by the protocol.~* Must agree to receive counseling related to teratogenic and other risks of lenalidomide~* Must agree not to donate blood or semen~* Must be willing to consent to two or more bone marrow aspirate procedures to be completed during study~Exclusion Criteria:~* Subjects previously receiving immunomodulating or immunosuppressive agents, or epigenetic or deoxyribonucleic acid (DNA) modulation agents~* Allergic reaction to thalidomide~* Renal insufficiency creatinine clearance (CrC1)\<40 mL/min by Cockcroft-Gault method)~* Prior history of cancer, other than MDS, unless the subject has been free of the disease for ≥ 5 years. (Basal cell carcinoma of the skin, carcinoma in situ of the cervix, or stage Tumor (T) 1a or T1b prostate cancer is allowed)~* Absolute neutrophil count (ANC) \< 500/uL~* Platelets \< 50,000/uL~* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3X upper limit of normal~* Uncontrolled hyperthyroidism or hypothyroidism~* Significant neuropathy~* Prior stem cell transplantation~* Anemia due to reasons other than MDS~* History of deep venous thrombosis (DVT) or pulmonary embolus (PE) within past 3 years~* Significant active cardiac disease within the past 6 months~* Known Human Immunodeficiency Virus (HIV) infection; known Hepatitis C infection or active Hepatitis B infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm #1 - Lenalidomide plus placebo (Type: EXPERIMENTAL): Lenalidomide 10 mg by mouth (PO) daily plus 2 placebo capsules for participants with a creatinine clearance ≥ 60 mL/min for at least 168 days until disease progression, intolerable side effects or withdrawal of consent. Lenalidomide 5 mg PO daily plus 2 placebo capsules for participants with a creatinine clearance ≥ 40 and \< 60 mL/min.
- Arm #2 - placebo (Type: PLACEBO_COMPARATOR): Three placebo capsules once daily for at least 168 days until disease progression occurred, intolerable side effects or withdrawal of consent.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete